IMPACT Inhibitors
Chemical inhibitors of IMPACT target various signaling pathways integral to its function in modulating cellular stress responses and protein synthesis regulation. LY294002 and Wortmannin, as specific inhibitors of phosphoinositide 3-kinases (PI3K), can disrupt the PI3K/Akt pathway, which is crucial for the activity of IMPACT. The inhibition of this pathway by LY294002 or Wortmannin compromises the ability of IMPACT to protect against stress-induced translational inhibition. Similarly, Rapamycin and its analogs, KU-0063794, PP242, Torin 1, and AZD8055, inhibit the mammalian target of rapamycin (mTOR), a key node in the PI3K/Akt/mTOR pathway. Since IMPACT interacts with components regulated by mTOR signaling, these inhibitors can reduce IMPACT's activity by disrupting necessary mTOR-dependent signaling.
Further, PD98059 and U0126 are selective inhibitors of MEK, which acts upstream of the extracellular signal-regulated kinase (ERK) pathway, a pathway that IMPACT's functioning may intersect with. By blocking MEK and the subsequent activation of ERK, these chemicals can hinder the role of IMPACT in managing cellular stress responses. SB203580 and SP600125 target p38 MAP kinase and c-Jun N-terminal kinase (JNK) respectively, both of which are involved in stress response pathways. Inhibition of these kinases by SB203580 and SP600125 can lead to an indirect reduction in IMPACT's functional activity as it is involved in these stress response pathways. Lastly, PF-4708671, a selective inhibitor of the p70 S6 kinase (S6K1), can disrupt the pathway downstream of mTOR, impacting the role of IMPACT in the regulation of protein synthesis under stress conditions, thus inhibiting its activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a specific inhibitor of phosphoinositide 3-kinases (PI3K), which are involved in various signaling pathways including those that regulate protein synthesis and cellular stress responses. Inhibition of PI3K can disrupt the signaling required for the activity of IMPACT, as IMPACT is known to modulate cellular stress responses, potentially reducing its functional capacity to protect against stress-induced translational inhibition. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin acts as a potent, irreversible inhibitor of PI3K. By inhibiting PI3K, wortmannin can impair the PI3K/Akt pathway, which is implicated in the regulation of translation and cellular stress responses. This impairment can indirectly lead to the functional inhibition of IMPACT, which is involved in these cellular processes. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an inhibitor of the mammalian target of rapamycin (mTOR), an important component of the PI3K/Akt/mTOR pathway. Since IMPACT interacts with components of the cellular machinery that are regulated by mTOR signaling, rapamycin can reduce the functional activity of IMPACT by inhibiting mTOR-dependent signaling pathways. | ||||||
KU 0063794 | 938440-64-3 | sc-361219 | 10 mg | $209.00 | ||
KU-0063794 specifically inhibits mTORC1 and mTORC2 complexes. Through inhibition of mTOR activity, this compound would inhibit the signaling pathways that IMPACT is involved in, particularly the ones related to the cellular stress response and translation regulation, thereby reducing IMPACT's functional activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a selective inhibitor of mitogen-activated protein kinase kinase (MEK), which acts upstream of the extracellular signal-regulated kinase (ERK) pathway. As IMPACT has a role in cellular responses to stress that may involve the ERK pathway, PD98059 can indirectly inhibit the function of IMPACT by blocking this pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is another MEK inhibitor that can prevent the activation of the ERK pathway. By inhibiting MEK and consequently the ERK pathway, U0126 can indirectly inhibit the function of IMPACT by disrupting signaling pathways that IMPACT may regulate in response to cellular stress. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a selective inhibitor of the p38 MAP kinase, which is involved in the response to stress stimuli and is part of the signaling pathways that IMPACT may modulate. Inhibition of p38 MAP kinase can thus indirectly inhibit the function of IMPACT by disrupting its associated stress response pathways. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which, like p38 MAP kinase, is implicated in stress response pathways. Inhibition of JNK can disrupt the proper functioning of IMPACT by inhibiting signaling pathways it is involved in, specifically those related to cellular stress responses. | ||||||
PF 4708671 | 1255517-76-0 | sc-361288 sc-361288A | 10 mg 50 mg | $179.00 $700.00 | 9 | |
PF-4708671 is a selective inhibitor of the p70 S6 kinase (S6K1), a downstream target of the PI3K/Akt/mTOR pathway. By inhibiting S6K1, this chemical can indirectly inhibit the function of IMPACT by disrupting signaling pathways that are crucial for protein synthesis and stress responses that IMPACT modulates. | ||||||
PP242 | 1092351-67-1 | sc-301606A sc-301606 | 1 mg 5 mg | $57.00 $172.00 | 8 | |
PP242 is an ATP-competitive inhibitor of mTOR that affects both mTORC1 and mTORC2. By inhibiting these complexes, PP242 can reduce the functional activity of IMPACT by disrupting the signaling pathways it is involved in, particularly those related to the protein synthesis machinery and cellular stress responses. | ||||||